Abstract
The prevalence of long-term antimalarial muscle and cardiac toxicity has been estimated at 6.5%.1 Antimalarial-induced cardiomyopathy is reversible in 45% of cases after treatment discontinuation and is associated with a 20% mortality rate.2

This publication has 1 reference indexed in Scilit: